Showing results (191-200 of 228) with videos related to

Sort By:
Pageof 23
Leukemia & Lymphoma|January 21, 2017
A phase 1 study of bortezomib and romidepsin in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, indolent B-cell lymphoma, peripheral T-cell lymphoma, or cutaneous T-cell lymphomaBeata Holkova, Victor Yazbeck, Maciej Kmieciak, et al.
Plant Science : an International Journal of Experimental Plant Biology|May 8, 2026
The cytokinin oxidase/dehydrogenase MdCKX4 regulates drought tolerance in Malus domesticaTong Li, Yu-Feng Zhang, Joy Xin-Yue Zhai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 31, 2025
Zanubrutinib and Venetoclax for Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma With and Without Del(17p)/TP53 Mutation: SEQUOIA Arm D ResultsMazyar Shadman, Talha Munir, Shuo Ma, et al.
Blood|June 11, 2021
Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited- duration therapyShuo Ma, John F Seymour, Danielle M Brander, et al.
Blood|April 27, 2019
Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variablesAndrew W Roberts, Shuo Ma, Thomas J Kipps, et al.
Blood Cancer Journal|February 19, 2021
Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradicationPin Lu, Shengchun Wang, Carrie A Franzen, et al.
Science Advances|September 3, 2025
Hybrid pneumatic-hydraulic actuation for MRI-guided robotic stereotactic neurointerventionShaoping Huang, Zhao He, Yi Chen, et al.
Blood Advances|July 24, 2025
Nivolumab in Combination with R-CHOP for Treatment-Naïve Diffuse Large B-Cell Lymphoma: An Evaluation of Safety and EfficacyOluwatobi Odetola, Shuo Ma, Jane N Winter, et al.
Blood Advances|November 23, 2020
Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysisAriela Noy, Sven de Vos, Morton Coleman, et al.
Blood Advances|October 23, 2023
Response-adapted, time-limited venetoclax, umbralisib, and ublituximab for relapsed/refractory chronic lymphocytic leukemiaBrian T Hill, Shuo Ma, Clive S Zent, et al.
Pageof 23